Current Treatments in Myopic Choroidal Neovascularization

Dr. Sebile Çomçalı

Ankara Bilkent City Hospital, Department of Ophthalmology, Ankara, Türkiye

ABSTRACT

Myopic choroidal neovascularization (mCNV) is a significant vision-threatening complication of pathologic myopia that often affects individuals under the age of 50, leading to substantial negative impacts on qual- ity of life. Pathologic myopia is the second most common cause of choroidal neovascularization, following age-related macular degeneration (AMD). If left untreated, it can result in extensive macular atrophy and scarring, leading to irreversible vision loss in a short period. Although verteporfin photodynamic therapy was used in previous years, its long-term effectiveness is limited. Due to the similarities in pathophysiology be- tween mCNV and other retinal angiogenic diseases, recent clinical studies and real-world experiences have demonstrated the efficacy of anti-vascular endothelial growth factor (anti-VEGF) injections in the treatment of mCNV. Consequently, this class of medications has replaced photodynamic therapy as first-line treatment.

Keywords: Degenerative myopia; Choroidal neovascularization; Vascular endothelial growth factor; Ranibizumab; Aflibercept; Bevacizumab

Referanslar

  1. Morgan IG, French AN, Ashby RS, Guo X, Ding X, He M, Rose KA. The epidemics of myopia: Aetiology and pre- vention. Prog Retin Eye Res. 2018 Jan;62:134-149. Epub 2017 Sep 23. [Crossref]  [PubMed]
  2. Wong TY, Ferreira A, Hughes R, Carter G, Mitchell P. Ep- idemiology and disease burden of pathologic myopia and myopic choroidal neovascularization: an evidence-based systematic review. Am J Ophthalmol. 2014 Jan;157(1):9- 25.e12. Epub 2013 Oct 5. [Crossref]  [PubMed]
  3. Curtin BJ, Karlin DB. Axial length measurements and fun- dus changes of the myopic eye. Am J Ophthalmol. 1971 Jan;71(1 Pt 1):42-53. [Crossref]  [PubMed]
  4. Hayashi K, Ohno-Matsui K, Shimada N, Moriyama M, Koji- ma A, Hayashi W, Yasuzumi K, Nagaoka N, Saka N, Yoshida T, Tokoro T, Mochizuki M. Long-term pattern of progression of myopic maculopathy: a natural history study. Ophthalmol- ogy. 2010 Aug;117(8):1595-611, 1611.e1-4. Epub 2010 Mar 5. [Crossref]  [PubMed]
  5. Neelam K, Cheung CM, Ohno-Matsui K, Lai TY, Wong TY. Choroidal neovascularization in pathological myopia. Prog Retin Eye Res. 2012 Sep;31(5):495-525. Epub 2012 Apr 28. [Crossref]  [PubMed]
  6. Ohno-Matsui K, Yoshida T, Futagami S, Yasuzumi K, Shi- mada N, Kojima A, Tokoro T, Mochizuki M. Patchy atrophy and lacquer cracks predispose to the development of cho- roidal neovascularisation in pathological myopia. Br J Oph- thalmol. 2003 May;87(5):570-3. [Crossref]  [PubMed]  [PMC]
  7. Wong TY, Ohno-Matsui K, Leveziel N, Holz FG, Lai TY, Yu HG, Lanzetta P, Chen Y, Tufail A. Myopic choroidal neovascularisation: current concepts and update on clinical management. Br J Ophthalmol. 2015 Mar;99(3):289-96. Epub 2014 Jul 1. [Crossref]  [PubMed]  [PMC]
  8. Tong JP, Chan WM, Liu DT, Lai TY, Choy KW, Pang CP, Lam DS. Aqueous humor levels of vascular endothelial growth factor and pigment epithelium-derived factor in pol- ypoidal choroidal vasculopathy and choroidal neovascular- ization. Am J Ophthalmol. 2006 Mar;141(3):456-62. [Crossref]  [PubMed]
  9. Teo KY, Ng WY, Lee SY, Cheung CM. Management of My- opic Choroidal Neovascularization: Focus on Anti-VEGF Therapy. Drugs. 2016 Jul;76(11):1119-33. [Crossref]  [PubMed]
  10. Wakabayashi T, Ikuno Y. Choroidal filling delay in choroidal neovascularisation due to pathological myopia. Br J Oph- thalmol. 2010 May;94(5):611-5. Epub 2009 Oct 21. [Crossref]  [PubMed]
  11. Yazar Z, Onen M. Myopic Choroidal Neovascular Membran. Gürelik G. Editor. Current Approaches in Basic Retinal Dis- eases 1 st ed. Ankara 2023. page 349-355.
  12. Inhoffen W, Ziemssen F. Morphological features of my- opic choroidal neovascularization: differences to neovas- cular age-related macular degeneration]. Ophthalmologe. 2012 Aug;109(8):749-57. German. [Crossref]  [PubMed]
  13. Lai TY, Cheung CM. Myopic Choroidal Neovascularization: Diagnosis and Treatment. Retina. 2016 Sep;36(9):1614-21. [Crossref]  [PubMed]
  14. Introini U, Casalino G, Querques G, Gimeno AT, Scotti F, Bandello F. Spectral-domain OCT in anti-VEGF treatment of myopic choroidal neovascularization. Eye (Lond). 2012 Jul;26(7):976-82. Epub 2012 Apr 27. [Crossref]  [PubMed]  [PMC]
  15. Iacono P, Giorno P, Varano M, Parravano M. Structural and optical coherence tomography angiography in myopic choroidal neovascularization: Agreement with conven- tional fluorescein angiography. Eur J Ophthalmol. 2021 Jan;31(1):149-157. Epub 2019 Oct 17. [Crossref]  [PubMed]
  16. Secrétan M, Kuhn D, Soubrane G, Coscas G. Long-term visual outcome of choroidal neovascularization in patho- logic myopia: natural history and laser treatment. Eur J Ophthalmol. 1997 Oct-Dec;7(4):307-16. [Crossref]  [PubMed]
  17. Tano Y. Pathologic myopia: where are we now? Am J Ophthalmol. 2002 Nov;134(5):645-60. [Crossref]  [PubMed]
  18. Virgili G, Menchini F. Laser photocoagulation for choroidal neovascularisation in pathologic myopia. Cochrane Database Syst Rev. 2005 Oct 19;(4):CD004765. [Crossref]  [PubMed]
  19. Blinder KJ, Blumenkranz MS, Bressler NM, Bressler SB, Donato G, Lewis H, et al. Verteporfin therapy of subfoveal choroidal neovascularization in pathologic myopia: 2-year results of a randomized clinical trial--VIP report no. 3. Oph- thalmology. 2003 Apr;110(4):667-73. [Crossref]  [PubMed]
  20. Hayashi K, Ohno-Matsui K, Shimada N, Moriyama M, Hayashi W, Wang J, et al. Long-term results of photody- namic therapy for choroidal neovascularization in Japanese patients with pathologic myopia. Am J Ophthalmol. 2011 Jan;151(1):137-147.e1. [Crossref]  [PubMed]
  21. Yoshida T, Ohno-Matsui K, Ohtake Y, Takashima T, Futag- ami S, Baba T, et al. Long-term visual prognosis of cho- roidal neovascularization in high myopia: a comparison be- tween age groups. Ophthalmology. 2002 Apr;109(4):712-9. [Crossref]  [PubMed]
  22. Yoshida T, Ohno-Matsui K, Yasuzumi K, Kojima A, Shimada N, Futagami S, et al. Myopic choroidal neovascularization: a 10-year follow-up. Ophthalmology. 2003 Jul;110(7):1297-305. [Crossref]  [PubMed]
  23. Tufail A, Patel PJ, Sivaprasad S, Amoaku W, Browning AC, Cole M, et al. Ranibizumab for the treatment of cho- roidal neovascularisation secondary to pathological my- opia: interim analysis of the REPAIR study. Eye (Lond). 2013 Jun;27(6):709-15. Epub 2013 Mar 1. Erratum in: Eye (Lond). 2013 Jun;27(6):786. Erratum in: Eye (Lond). 2014 Mar;28(3):365. [Crossref]  [PubMed]  [PMC]
  24. Tufail A, Narendran N, Patel PJ, Sivaprasad S, Amoaku W, Browning AC, et al. Ranibizumab in myopic choroidal neovascularization: the 12-month results from the REPAIR study. Ophthalmology. 2013 Sep;120(9):1944-5.e1. [Crossref]  [PubMed]
  25. Wolf S, Balciuniene VJ, Laganovska G, Menchini U, Ohno-Matsui K, Sharma T, et al.; RADIANCE Study Group. RADIANCE: a randomized controlled study of ranibizumab in patients with choroidal neovascularization secondary to pathologic myopia. Ophthalmology. 2014 Mar;121(3):682-92.e2. Epub 2013 Dec 8. [Crossref]  [PubMed]
  26. Chen Y, Sharma T, Li X, Song Y, Chang Q, Lin R, et al. Ranibizumab Versus Verteporfin Photodynamic Therapy In Asian Patients With Myopic Choroidal Neovascularization: Brilliance, a 12-Month, Randomized, Double-Masked Study. Retina. 2019 Oct;39(10):1985-1994. [Crossref]  [PubMed]  [PMC]
  27. Hamilton RD, Clemens A, Minnella AM, Lai TYY, Dai H, Sakamoto T, et al.; LUMINOUS study group. Real-world effectiveness and safety of ranibizumab for the treatment of myopic choroidal neovascularization: Results from the LU- MINOUS study. PLoS One. 2020 Jan 21;15(1):e0227557. [Crossref]  [PubMed]  [PMC]
  28. Ikuno Y, Ohno-Matsui K, Wong TY, Korobelnik JF, Vitti R, Li T, et al.; MYRROR Investigators. Intravitreal Afliber- cept Injection in Patients with Myopic Choroidal Neovas- cularization: The MYRROR Study. Ophthalmology. 2015 Jun;122(6):1220-7. Epub 2015 Mar 4. [Crossref]  [PubMed]
  29. Gharbiya M, Allievi F, Conflitti S, Esposito M, Scavella V, Moramarco A, et al. Intravitreal bevacizumab for treatment of myopic choroidal neovascularization: the second year of a prospective study. Clin Ter. 2010;161(3):e87-93. [PubMed]
  30. Iacono P, Parodi MB, Papayannis A, Kontadakis S, Sheth S, Bandello F. Intravitreal bevacizumab therapy on an as- per-needed basis in subfoveal choroidal neovascularization secondary to pathological myopia: 2-year outcomes of a pro- spective case series. Retina. 2011 Oct;31(9):1841-7. [Crossref]  [PubMed]
  31. Ikuno Y, Sayanagi K, Soga K, Sawa M, Tsujikawa M, Gomi F, et al. Intravitreal bevacizumab for choroidal neovascular- ization attributable to pathological myopia: one-year results. Am J Ophthalmol. 2009 Jan;147(1):94-100.e1. Epub 2008 Sep 6. [Crossref]  [PubMed]
  32. Gharbiya M, Giustolisi R, Allievi F, Fantozzi N, Mazzeo L, Scavella V, et al.Choroidal neovascularization in patho- logic myopia: intravitreal ranibizumab versus bevacizum- ab--a randomized controlled trial. Am J Ophthalmol. 2010 Mar;149(3):458-64.e1. [Crossref]  [PubMed]
  33. Iacono P, Parodi MB, Papayannis A, Kontadakis S, Sheth S, Cascavilla ML, Bandello F. Intravitreal ranibizumab versus bevacizumab for treatment of myopic choroidal neovascular- ization. Retina. 2012 Sep;32(8):1539-46. [Crossref]  [PubMed]
  34. Peiretti E, Vinci M, Fossarello M. Intravitreal bevacizum- ab as a treatment for choroidal neovascularisation second- ary to myopia: 4-year study results. Can J Ophthalmol. 2012 Feb;47(1):28-33. [Crossref]  [PubMed]
  35. Oishi A, Yamashiro K, Tsujikawa A, Ooto S, Tamura H, Nakata I, Miyake M, Yoshimura N. Long-term effect of intravitreal injection of anti-VEGF agent for visual acuity and chorioretinal atrophy progression in myopic choroidal neovascularization. Graefes Arch Clin Exp Ophthalmol. 2013 Jan;251(1):1-7. Epub 2012 Apr 19. [Crossref]  [PubMed]
  36. Ruiz-Moreno JM, Montero JA, Arias L, Araiz J, Gomez-Ulla F, Silva R, Piñero DP. Three versus one intravitreal bevaci- zumab injections as initial protocol to treat myopic choroidal neovascularization. Acta Ophthalmol. 2012 Feb;90(1):e82-3. Epub 2011 Apr 6. [Crossref]  [PubMed]
  37. Kung YH, Wu TT, Huang YH. One-year outcome of two different initial dosing regimens of intravitreal ranibizum- ab for myopic choroidal neovascularization. Acta Ophthal- mol. 2014 Dec;92(8):e615-20. Epub 2014 Jun 12. [Crossref]  [PubMed]
  38. Gao L, Song Y, Sun X, Zhang J, Liu Y, Chen Y, Wu Z, Jian Y, Liu X, Lv L, Chen S, Wang YS, Chen N, Ke X, Zhang F. Safety and efficacy of intravitreal injection of conbercept for the treatment of patients with choroidal neovascularization secondary to pathological myopia: Results from the SHINY study. Acta Ophthalmol. 2024 Jun;102(4):e577-e586. Epub 2023 Nov 27. [Crossref]
  39. Holz FG, Tufail A, Leveziel N, Lai TY, Lanzetta P, Wong TY, et al.; RADIANCE Study Group. Ranibizumab in Myopic Choroidal Neovascularization: A Subgroup Analysis by Eth- nicity, Age, and Ocular Characteristics in RADIANCE. Oph- thalmologica. 2016;236(1):19-28. Epub 2016 Jun 7. [Crossref]  [PubMed]
  40. Nawar AE, Shafik HM. Pilot study of ziv-aflibercept in my- opic choroidal neovascularisation patients. BMC Ophthal- mol. 2020 Oct 19;20(1):414. [Crossref]  [PubMed]  [PMC]
  41. Glachs L, Embacher S, Berghold A, Wildner B, Miche- litsch M, Tscherne A, Wedrich A, Posch-Pertl L. Treatment of myopic choroidal neovascularization: a network me- ta-analysis and review. Graefes Arch Clin Exp Ophthalmol. 2024 Jun;262(6):1693-1722. Epub 2023 Nov 11. [Crossref]  [PubMed]  [PMC]